Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.79 EUR
Change Today -0.05 / -1.30%
Volume 155.5K
VLA On Other Exchanges
EN Paris
As of 11:35 AM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

valneva se (VLA) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/8/14 - €5.21
52 Week Low
01/13/15 - €3.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VALNEVA SE (VLA)

Related News

No related news articles were found.

valneva se (VLA) Related Businessweek News

No Related Businessweek News Found

valneva se (VLA) Details

Valneva SE, a biotechnology company, develops, manufactures, distributes, and commercializes vaccines for infectious diseases worldwide. The company offer IXIARO/JESPECT, a vaccine to prevent Japanese encephalitis for travelers, military, and populations of endemic regions; JEEV, a vaccine to protect children and adults from Japanese encephalitis; and Dukoral, a vaccine against cholera and traveler’s diarrhea caused by enterotoxigenic escherichia coli. Its development programs include EB66 Pandemic Influenza, which has completed Phase 1 clinical trials in the United States and is in a new drug application Phase in Japan; Pseudomonas aeruginosa program, which is in Phase II/III development trial; and IC31 partnered programs comprising Phase I and II studies in the field of tuberculosis. The company also develops IC84, a vaccine candidate that is in a Phase I safety and immunogenicity study for the prevention of Clostridium difficile; and a multivalent protein subunit based vaccine candidate, which is nearing the completion of pre-clinical development and entering the IND process for the prevention of Lyme disease. In addition, it develops EB66 human programs and EB66 veterinary programs; and antibodies to treat infectious diseases and cancer. Further, the company offers EB66 cell line, a proprietary embryonic stem cell-based technology for the production of various human and veterinary viral and therapeutic vaccines; and IC31, a synthetic vaccine adjuvant that non-specifically enhances and shapes the immune response to specific antigenic components of vaccines through the targeted activation of the immune system. Valneva SE is headquartered in Lyon, France.

400 Employees
Last Reported Date: 05/12/15

valneva se (VLA) Top Compensated Officers

Chairman of The Management Board, Chief Execu...
Total Annual Compensation: €512.0K
Co-President, Chief Business Officer, Managin...
Total Annual Compensation: €541.6K
Chief Financial Officer and Member of The Man...
Total Annual Compensation: €384.0K
Compensation as of Fiscal Year 2013.

valneva se (VLA) Key Developments

Valneva SE Presents at French Life Science Days conference, Jun-17-2015

Valneva SE Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

Valneva SE Presents at CF&B Spring European Midcap Event 2015, Jul-01-2015

Valneva SE Presents at CF&B Spring European Midcap Event 2015, Jul-01-2015 . Venue: Pullman Paris Tour Eiffel, 18 Avenue de Suffren, Paris, France.

Valneva SE Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Re-Confirms Revenue Guidance for the Year 2015

Valneva SE reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues & grants of EUR 19,501,000 compared to EUR 7,095,000 a year ago. Net loss was EUR 5,019,000 compared to EUR 7,112,000 a year ago. LBITDA was EUR 3,063,000 compared to EUR 3,293,000 a year ago. Net cash used in operating activities was EUR 10,947,000 compared to EUR 10,037,000 a year ago, primarily from the operating loss in connection with the Group's R&D activities and from an increase in working capital due to a significant reduction of trade payables. Revenue growth mainly driven by IXIARO®'s strong first quarter sales (EUR 9.7 million) and product sales from the newly acquired DUKORAL® and Nordics vaccine distribution business (EUR 5.4 million). Operating loss decreased by EUR 0.5 million to minus EUR 6.0 million in the first quarter 2015 compared to minus EUR 6.4 million in the first quarter 2014. The company re-confirmed its 2015 revenue expectation of approximately EUR 75 million to EUR 85 million, compared to EUR 42.4 million in 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VLA:FP €3.79 EUR -0.05

VLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr322.00 DKK +7.50
Emergent BioSolutions Inc $32.86 USD +0.50
Green Cross Corp/South Korea 250,000 KRW -17,000.00
Virbac SA €198.25 EUR +0.50
Zoetis Inc $48.15 USD -0.16
View Industry Companies

Industry Analysis


Industry Average

Valuation VLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.2x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALNEVA SE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at